March 2, 2021 – The National Institutes of Health has launched the next version of the Accelerating Medicines Partnership (AMP) Alzheimer’s disease program (AMP AD 2.0) to expand the open science, big data approach for identifying biological targets for therapeutic intervention. Read the full NIH press release.
February 2021 – A group of students from the University of Arizona launched a biotechnology start-up called Cliacept (CLEE-a-cept). Cliacept is working to develop an effective and affordable treatment for Alzheimer’s disease (AD).
The Model Organism Development and Evaluation for Late-onset Alzheimer’s Disease (MODEL-AD) consortium discussed their goals, including the development of new models based on recent human genetics, the alignment of AD pathophysiology in mouse models and human studies, the staging of disease progression, and preclinical testing based on translatable biomarkers.
Dr. Gregory Carter is an Associate Professor at The Jackson Laboratory, Bar Harbor, ME. He combines genetic, genomic, imaging, and other data resources to understand the causes and progression of Alzheimer’s disease.